Retrospective analysis identifies predictors of dose modification for niraparib

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A retrospective analysis of the phase III NOVA trial identified two baseline characteristics, patient body weight less than 170 pounds (77 kilograms) or platelet count of <150,000/µL to be significant factors for grade III or IV thrombocytopenia.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login